Doravirine/Islatravir (DOR/ISL) in Pediatric Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are <18 Years of Age and Weigh ≥35 kg (MK-8591A-028)
Clinical trial NCT04295772 · COMPLETED
Trial details
- NCT number
- NCT04295772
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-11-26
- Primary completion
- 2021-12-21
- Enrollment
- 42
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.